Litigation Details for SUN PHARMACEUTICAL INDUSTRIES, LTD. v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

« Back to Dashboard

SUN PHARMACEUTICAL INDUSTRIES, LTD. v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

Docket	2:19-cv-21733	Date Filed	2019-12-20
Court	District Court, D. New Jersey	Date Terminated	2020-05-14
Cause		Assigned To	Claire Claudia Cecchi
Jury Demand		Referred To	Mark Falk
Parties	NOVARTIS PHARMACEUTICALS CORP.
Patents	6,284,804; 6,359,016; 8,846,650; 9,149,486; 9,345,714; 9,402,805
Link to Docket	External link to docket

Details for SUN PHARMACEUTICAL INDUSTRIES, LTD. v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-12-20				External link to document
2019-12-19	1	Complaint	. 6,284,804 (“the ’804 patent”), U.S. Patent No. 6,359,016 (“the ’016 patent”), the ’650 patent, the … claim of U.S. Patent Nos. 9,402,805 (“the ’805 patent”), 9,345,714 (“the ’714 patent”), 9,149,486 (“…(“the ’486 patent”), and 8,846,650 (the ’650 patent”) and the claims of the ‘805 patent are invalid for…action regarding allegations of patent infringement arising under the patent laws of the United States, Title…certifications for each patent listed in the Orange Book for the RLD: (i) there are no patents listed in the Orange	External link to document

Sun Pharmaceutical Industries v. Novartis Pharmaceuticals: Litigation Summary and Patent Analysis

Last updated: August 19, 2026

Sun Pharmaceutical Industries Ltd. challenged Novartis Pharmaceuticals Corp.’s patent rights covering generic fingolimod hydrochloride capsules, the generic equivalent of Gilenya. The action, No. 2:19-cv-21733, was filed in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework after Sun submitted an abbreviated new drug application containing a Paragraph IV certification.

The dispute centered on Novartis patent rights covering fingolimod treatment for multiple sclerosis, including U.S. Patent No. 9,089,587. The case was resolved through a stipulated dismissal rather than a reported merits decision. Public docket materials do not provide the complete commercial terms of the parties’ resolution.

What drug and patents were involved in Sun v. Novartis?

The litigation involved fingolimod hydrochloride capsules, marketed by Novartis as Gilenya.

Item	Detail
Brand product	Gilenya
Active ingredient	Fingolimod hydrochloride
Dosage form	Oral capsules
Principal indication	Relapsing forms of multiple sclerosis
NDA holder	Novartis Pharmaceuticals Corp.
ANDA sponsor	Sun Pharmaceutical Industries Ltd.
Court	U.S. District Court for the District of New Jersey
Case number	2:19-cv-21733
Statutory framework	Hatch-Waxman Act
Patent issue	Validity, enforceability and infringement of Gilenya-related patent claims

Novartis’ Gilenya patent estate included method-of-use patents directed to administering fingolimod for multiple sclerosis. The litigation was not primarily a compound-patent dispute. The key commercial protection came from patents covering the clinical use and dosing of fingolimod after the original compound protection had expired.

What is U.S. Patent No. 9,089,587?

U.S. Patent No. 9,089,587 is associated with methods of treating multiple sclerosis using fingolimod. The patent was assigned to Novartis-related entities and was listed in connection with Gilenya.

The patent’s commercial importance arose from claims directed to the use of fingolimod in patients with relapsing forms of multiple sclerosis, including the once-daily 0.5 mg regimen used for Gilenya. Its term extended into 2027, subject to any applicable patent-term adjustment and pediatric exclusivity.

Other Gilenya-related patents and regulatory protections existed outside the single patent at issue in a particular ANDA case. Patent exposure therefore depended on the exact ANDA formulation, labeling carve-outs, certification language and patents asserted in the complaint and counterclaims.

What was Sun’s legal position in the Gilenya patent litigation?

Sun’s ANDA filing triggered the Hatch-Waxman litigation process. A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

Sun’s position would have required it to establish, depending on the patent and claim:

1. That its proposed fingolimod product did not infringe the asserted claims.
2. That the asserted claims were invalid, including for obviousness or lack of written description.
3. That any asserted patent was unenforceable.
4. That FDA approval and commercial launch should not be blocked beyond the lawful patent term.

Novartis’ counterclaims sought the standard Hatch-Waxman remedy: a judgment that Sun’s ANDA product would infringe the asserted patent claims, together with an order delaying FDA approval or commercial launch until the statutory stay and patent term had expired.

When did Sun v. Novartis begin and how was it resolved?

Procedural event	Reported position
Complaint filed	2019
Court	District of New Jersey
Case number	2:19-cv-21733
Action type	ANDA patent litigation
Plaintiff	Sun Pharmaceutical Industries Ltd.
Defendants	Novartis Pharmaceuticals Corp. and related Novartis entities
Resolution	Stipulated dismissal
Merits trial	No reported final judgment on validity or infringement
Public settlement terms	Not fully disclosed in the docket

The case did not produce a published trial opinion adjudicating the validity of the asserted Gilenya patent claims. The stipulated dismissal ended the specific action without creating a precedential ruling on Sun’s noninfringement or invalidity theories.

A dismissal in this context does not establish that the patent was valid or infringed. It indicates that the parties resolved the case or otherwise agreed to terminate the action before a final merits determination.

Did Sun and Novartis enter a settlement agreement?

The docket reflects a stipulated resolution, but the complete settlement agreement was not publicly available as part of the court’s merits record.

In Hatch-Waxman cases, such resolutions commonly address:

• The earliest permitted generic launch date.
• Whether Sun receives a license to enter before patent expiration.
• Restrictions on marketing and manufacturing.
• Treatment of pediatric exclusivity.
• Acceleration provisions if the patent is invalidated or forfeited.
• Allocation of litigation costs.
• Confidentiality and non-admission provisions.

The stipulated dismissal alone does not establish the launch date. Any commercial entry date must be determined from the settlement agreement, FDA approval status, applicable patent listings and subsequent regulatory events.

What was the Orange Book status of Gilenya?

The FDA Orange Book listed Gilenya-related patents covering the product and its approved uses. Orange Book listings matter because an ANDA applicant must address each listed patent through a certification or statement.

The principal categories were:

Protection category	Relevance to Gilenya
Compound protection	Covered fingolimod-related chemical matter but was no longer the principal barrier by the time of the 2019 litigation
Method-of-use protection	Covered fingolimod treatment for multiple sclerosis
Dosage and regimen protection	Supported protection for the once-daily 0.5 mg regimen
Regulatory exclusivity	Separate from patent term and controlled by FDA exclusivity rules
Pediatric exclusivity	Could extend relevant FDA protection by six months if statutory requirements were met

The Orange Book listing of a patent does not mean the patent will survive a validity challenge. It creates the procedural mechanism for an NDA holder to assert the patent after a Paragraph IV certification.

When did Gilenya lose patent and regulatory exclusivity?

Gilenya’s exclusivity expired in stages rather than on a single date.

The original compound-related protection did not control the entire commercial life of the product. Later method-of-use patents extended protection for particular approved uses and dosing regimes. The most important Gilenya patent barriers extended into the 2020s, including protection associated with U.S. Patent No. 9,089,587 through approximately 2027, subject to term adjustments and statutory extensions.

Exclusivity type	Commercial effect
New chemical entity exclusivity	Delayed ANDA submission for the statutory period after approval
Patent protection	Could block approval or launch if valid and infringed
Pediatric exclusivity	Could add six months to eligible protection
Hatch-Waxman 30-month stay	Temporarily restricted FDA approval after timely patent litigation
First-filer exclusivity	Potentially relevant if an ANDA applicant qualified as a first Paragraph IV filer

Patent expiration did not automatically produce immediate generic sales. FDA approval, manufacturing readiness, supply arrangements, settlement restrictions and any remaining listed patents could affect entry timing.

What litigation affected Gilenya’s patent estate?

Novartis litigated Gilenya-related patents against multiple generic applicants. The most significant legal background involved challenges to method-of-use patents covering fingolimod treatment for multiple sclerosis.

In related federal litigation, courts considered whether the asserted fingolimod treatment claims were invalid as obvious. The Federal Circuit’s treatment of related Gilenya patent disputes reduced the predictability of relying solely on method-of-use claims as a long-term barrier. Each later ANDA case still required claim-specific analysis because different applicants could present different products, labels and invalidity arguments.

The Sun case itself did not generate a reported merits decision that resolved the full patent estate. Its value for market analysis is therefore procedural and commercial rather than precedential.

How strong was Novartis’ Gilenya patent estate?

Novartis had a meaningful but declining patent position.

Strengths

• Gilenya had a large commercial market in multiple sclerosis.
• Method-of-use claims could delay approval and create litigation leverage.
• The 0.5 mg regimen was closely connected to the approved product.
• ANDA plaintiffs faced the cost and timing burden of district-court litigation.
• A valid listed patent could delay approval even after earlier compound protection had expired.

Weaknesses

• The foundational compound protection was no longer the principal barrier in the 2019 dispute.
• Method-of-use claims faced obviousness challenges.
• Generic applicants could use labeling strategies to omit patented indications where legally permissible.
• Multiple generic defendants increased the prospect of coordinated challenges.
• A stipulated dismissal did not strengthen the patent through a judicial validity ruling.
• Patent protection was finite and concentrated in a limited number of later-expiring rights.

The estate was stronger as a litigation and timing tool than as an unlimited barrier to generic competition. Its value depended on the scope of the asserted claims and the ability to connect the generic label to the patented method.

What generic entry risks existed for Gilenya?

The principal risks were:

1. Paragraph IV litigation. Generic applicants could challenge method-of-use patents before launch.
2. At-risk launch. A generic could launch before final resolution, accepting potential damages exposure.
3. Label carve-outs. Applicants could omit patented indications or dosing information if FDA labeling rules allowed.
4. Multiple challengers. Several ANDA applicants could erode the practical value of a single settlement.
5. Patent invalidation. A successful obviousness challenge could remove the principal barrier for all later entrants.
6. Settlement acceleration. A license could establish a fixed entry date earlier than the full patent expiration.
7. Manufacturing competition. Once approval was available, price erosion could be rapid because fingolimod is a small-molecule product rather than a biologic.

Was biosimilar risk relevant to Gilenya?

No. Gilenya is a small-molecule pharmaceutical regulated under the ANDA pathway, not a biologic regulated through the biosimilar pathway under the Public Health Service Act.

The relevant competitors were generic fingolimod applicants, not biosimilar developers. The commercial analysis therefore turns on ANDA approval, Paragraph IV certifications, 180-day exclusivity, formulation equivalence and patent settlements.

How did Sun v. Novartis compare with biologic patent litigation?

Issue	Gilenya and Sun v. Novartis	Biologic patent litigation
FDA pathway	ANDA	351(k) biosimilar application
Product type	Small molecule	Biologic
Main competitor	Generic drug	Biosimilar or interchangeable biosimilar
Patent mechanism	Orange Book and Paragraph IV	Patent dance, BPCIA litigation
Substitution	Governed by generic substitution laws	Depends on interchangeability status
Formulation risk	Usually narrower technical scope	Often substantial manufacturing and formulation complexity
Launch economics	Rapid price erosion is common	Discount and uptake vary by product

What were the commercial consequences for Novartis and Sun?

For Novartis, Gilenya was a major multiple-sclerosis product, but revenue faced pressure from newer therapies and generic competition. Patent settlement timing could protect revenue during the final years of market exclusivity while avoiding the cost and uncertainty of trial.

For Sun, the case provided a route to commercialize fingolimod without waiting for a final validity decision. The value of the ANDA depended on approval timing, the settlement’s permitted launch date, manufacturing capacity and the number of competing generic applicants.

The relevant revenue exposure was therefore tied to the period between FDA approval and the authorized generic entry date. A single generic entrant could materially reduce price, while multiple entrants would typically accelerate erosion.

What is the current litigation status of Sun v. Novartis?

The specific action was resolved by stipulated dismissal and is not a pending merits dispute. No reported final judgment in the case invalidated or upheld the asserted Gilenya patent claims.

The dismissal did not eliminate Novartis’ broader patent estate, nor did it independently establish a public generic launch date. The commercial outcome must be read together with FDA approval records, Orange Book listings and any publicly reported settlement or licensing terms.

Key Takeaways

• Sun’s action challenged Novartis patent protection for generic fingolimod, the active ingredient in Gilenya.
• The dispute arose from a Paragraph IV ANDA certification.
• U.S. Patent No. 9,089,587 was a central Gilenya-related method-of-use patent.
• The case ended through stipulated dismissal rather than a reported merits judgment.
• Public docket materials do not disclose the complete settlement terms or establish the commercial launch date.
• Gilenya faced generic, not biosimilar, competition.
• Novartis’ later-expiring method-of-use patents provided litigation leverage but faced validity and labeling challenges.
• Generic entry risk increased as compound protection expired and multiple ANDA applicants challenged the remaining patent estate.

FAQs About Sun Pharmaceutical Industries v. Novartis

What generic drug was Sun seeking to market?

Sun was seeking approval for generic fingolimod hydrochloride capsules, the generic equivalent of Gilenya.

Did Sun win the Gilenya patent case?

There was no reported merits judgment declaring Sun the prevailing party. The action ended through a stipulated dismissal.

Did the case invalidate U.S. Patent No. 9,089,587?

No reported decision in this case invalidated the patent. The dismissal did not resolve the patent’s validity.

Was Gilenya subject to a biosimilar challenge?

No. Fingolimod is a small-molecule drug, so competitors proceed through the ANDA generic-drug pathway.

Does the dismissal reveal Sun’s generic launch date?

No. The stipulated dismissal by itself does not state the settlement’s commercial launch terms or establish the authorized launch date.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. U.S. Food and Drug Administration. (2010). Gilenya prescribing information. Novartis Pharmaceuticals Corporation.
3. United States District Court for the District of New Jersey. (2019). Sun Pharmaceutical Industries, Ltd. v. Novartis Pharmaceuticals Corp., No. 2:19-cv-21733.
4. United States Patent and Trademark Office. (2015). U.S. Patent No. 9,089,587: Fingolimod for use in treating multiple sclerosis.
5. Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals International Ltd., 923 F.3d 1051 (Fed. Cir. 2019).